A Slight (Immaterial) Setback In Post-Surgical Endometrial Tumors, With Chemo And Pembrolizumab...

This morning, Merck released top line results for a trial designed to show enhanced survival from Keytruda in post surgical settings, for certain endometrial cancers in women. It is immaterial, because Rahway already possesses two approvals for pembrolizumab in such cancers. [Our prior mention, here -- as background.]

The stock is rising slightly on the news, as proof of immateriality. So, onward, the juggernaut rumbles -- (perhaps to confirm) this cogent analysis, from Fierce:

. . .While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in newly diagnosed patients has fallen short.

Adjuvant treatment with Keytruda and chemotherapy -- with or without radiotherapy -- failed to hit the mark for disease-free survival (DFS) in newly diagnosed, high-risk endometrial cancer patients who received surgery with curative intent, according to an interim analysis of Merck’s late-stage KEYNOTE-B21 study. DFS refers to the length of time after a primary treatment ends that a patient survives without any signs or symptoms of their cancer. . . .

Now you know -- smiling and trusting all is well, in the soaked South, after a hectic weather night. . . onward.

नमस्ते